One of the major impediments to drug development is low aqueous solubility and thus poor
bioavailability, which leads to insufficient clinical utility. Around 70–80% of drugs in the …

The burden of irreversible vision loss from Glaucoma continues to rise. While the disease
pathogenesis is not well understood, intraocular pressure (IOP) is the only modifiable risk …

Sustained drug delivery strategies have many potential benefits for treating a range of
diseases, particularly chronic diseases that require treatment for years. For many chronic …

Although once daily anti-glaucoma drug therapy is a current clinical reality, most therapies
require multiple dosing and there is an unmet need to develop convenient, safe, and …

Glaucoma is a progressive optic neuropathy and a leading cause of irreversible blindness.
The disease has conventionally been characterized by an elevated intraocular pressure …

Background Polymers are essential components of many drug delivery systems and
biomedical products. Despite the utility of many currently available polymers, there exists a …

In the real-world setting, there is suboptimal compliance with treatments that require frequent
administration and assessment visits. This undertreatment frequently has negative …

A number of pharmacological targets are exploited to modify the parameters in the
Goldmann equation and reduce the intraocular pressure (IOP). This strategy constitutes the …

The eye has anatomical structures that function as robust static and dynamic barriers,
limiting the penetration, residence time, and bioavailability of medications administered …

Objective To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10 and
15 µg bimatoprost implant in patients with open-angle glaucoma (OAG) or ocular …